A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.

Trial Profile

A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 23 Nov 2012 Company 'GlaxoSmithKline' added as reported by ClinicalTrials.gov.
    • 05 Oct 2010 The status of this trial is uncertain because development of albinterferon alfa 2B has been discontinued, as reported by a Novartis media release.
    • 01 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top